Login / Signup

The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.

Tomoyuki SatakeChigusa MorizaneYuta MarukiAkihiro OhbaYoshikuni NagashioShunsuke KondoSusumu HijiokaHideki UenoTakuji Okusaka
Published in: International journal of clinical oncology (2022)
) in non-DV patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • squamous cell carcinoma
  • locally advanced
  • radiation therapy
  • patient reported outcomes
  • rectal cancer